Abstract:Objective: The purpose of this study was to monitor iron clearance from the liver by means of T2 and T2* mapping after administration of an ultrasmall superparamagnetic iron oxide (USPIO) agent. Materials and methods: The study was performed using ferumoxytol (Feraheme), a USPIO agent that has been approved by the US Food and Drug Administration for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. Six healthy human participants without anemia or preexisting iron overload were prospectively included. The cohort comprised 4 men and 2 postmenopausal women, aged 22 to 57 years. T2 and T2* mapping of the liver were performed at 1.5 T using multiple spin echo and multiple gradient echo sequences, respectively. After baseline imaging, ferumoxytol was injected intravenously at a dose of 5 mg Fe/kg body weight. Imaging was repeated at 3 days, 1 month, and every 2 months thereafter for up to 11 months or until liver T2* had recovered to 24 milliseconds, the threshold used to define iron deposition. For each examination, maps of the relaxation rates R2 (= 1/T2) and R2* (= 1/T2*) were generated by fitting the signal intensity data as a function of echo time to a monoexponential decay. Results: No adverse reactions to ferumoxytol injection occurred. The magnetic resonance (MR) responses to ferumoxytol varied widely among the participants. Liver R2* increased from a mean value of 35.6 s (range, 28.7-40.9 s) at baseline to a mean value of 241 s (range, 161-417 s) 3 days after administration. Liver R2 increased from 19.4 s (range, 16.6-23.8 s) at baseline to 45.3 s (range, 34.4-58.5 s) at 3 days. There was also a large variation in iron clearance times. In 1 participant, MR relaxation rates had recovered to baseline by 3 months, whereas, in 3 participants, liver R2* remained elevated at 11 months (R2* > 55 s, ie, T2* < 18 milliseconds). In these 3 participants, liver R2 also remained marginally higher at 11 months than corresponding baseline values. Conclusions: Iron deposition in the liver after a 5 mg Fe/kg dose of ferumoxytol may alter signal contrast on MR images for several months after administration. This is an important consideration in the use of USPIO agents for diagnostic purposes.

Specific biological responses following dextran-coated ultra-small superparamagnetic particles of iron oxides administration

An Insight into the Metabolic Responses of Ultra-Small Superparamagnetic Particles of Iron Oxide Using Metabonomic Analysis of Biofluids.

A Metabonomic Analysis of Organ Specific Response to USPIO Administration.

Magnetic resonance signal detection of superparamagnetic iron oxide nanoparticles and its biological effects on endothelial cells]

NMR-based Metabonomic Analyses of the Effects of Ultrasmall Superparamagnetic Particles of Iron Oxide (USPIO) on Macrophage Metabolism

Hepatic and renal cellular cytotoxic effects of heparin-coated superparamagnetic Iron oxide nanoparticles

Understanding the Metabolic Fate and Assessing the Biosafety of MnO Nanoparticles by Metabonomic Analysis

Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells.

MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults

In vivo toxicology of carbon dots by 1H NMR-based metabolomics.

The Bioavailability, Biodistribution, and Toxic Effects of Silica-Coated Upconversion Nanoparticles in Vivo

Uncovering the Fate and Risks of Intravenously Injected Prussian Blue Nanoparticles in mice by an Integrated Methodology of Toxicology, Pharmacokinetics, Proteomics, and Metabolomics

The Effect of Iron Oxide Magnetic Nanoparticles on Smooth Muscle Cells

Effects of DMSA-coated Fe3O4 Nanoparticles on the Transcription of Genes Related to Iron and Osmosis Homeostasis.

Parallel Comparative Studies on Mouse Toxicity of Oxide Nanoparticle- and Gadolinium-Based T1 MRI Contrast Agents

Blood Circulation, Biodistribution, and Pharmacokinetics of Dextran-Modified Black Phosphorus Nanoparticles

Study of dextran-coated superparamagnetic iron oxides nanoparticles as MRI constrast agent

In Vivo Assessment of Hepatotoxicity, Nephrotoxicity and Biodistribution Using 3-Aminopropyltriethoxysilane-coated Magnetic Nanoparticles (Apts-Mnps) in ICR Mice

Investigation of the Genetic Toxicity by Dextran-Coated Superparamagnetic Iron Oxide Nanoparticles (SPION) in HepG2 Cells Using the Comet Assay and Cytokinesis-Block Micronucleus Assay

Effects of Biodegradable Biomedical Porous MnO2 Nanoparticles on Blood Components and Functions.

Doxorubicin Loaded Dextran-coated Superparamagnetic Iron Oxide Na-noparticles with Sustained Release Property: Intracellular Uptake, Phar-macokinetics and Biodistribution Study